P
Profusa, Inc. (PFSA)
NCM – Real Time Price. Currency in USD
0.96
-0.03 (-2.56%)
Market open: Aug 12, 2026, 11:23 AM EDT
0.96
-0.03 (-2.74%)
Previous after-hours: Aug 11, 2026, 7:47 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.96
-0.03 (-2.56%)
Market open: Aug 12, 2026, 11:23 AM EDT
0.96
-0.03 (-2.74%)
Previous after-hours: Aug 11, 2026, 7:47 PM EDT
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
| Name | Position |
|---|---|
| Dr. Chung-Bin Hwang Ph.D. | President |
| Mr. David Icke | Head of Digital Health Business |
| Mr. Fred S. Knechtel | Chief Financial Officer |
| Mr. Jack E. Stover CPA | CEO & Executive Chairman |
| Mr. Sean Givens | Head of Government Business |
| Mr. William McMillan | Co-founder, Chief Scientific Officer & Head of Research |
| Date | Type | Document |
|---|---|---|
| 2026-07-31 | 8-K | ea0300017-8k_profusa.htm |
| 2026-07-27 | 8-K | ea0298832-8k_profusa.htm |
| 2026-07-06 | 8-K | ea0297130-8k_profusa.htm |
| 2026-06-23 | 8-K | ea0295656-8k_profusa.htm |
| 2026-06-08 | 8-K | ea0293894-8k_profusa.htm |
| 2026-05-26 | DEF 14A | ea0289795-02.htm |
| 2026-05-26 | ARS | ea0289795-04.pdf |
| 2026-05-26 | 8-K | ea0292151-8k_profusa.htm |
| 2026-05-18 | 8-K | ea0291342-8k_profusa.htm |
| 2026-05-15 | 8-K | ea0291023-8k_profusa.htm |